Clinical Trial Update: Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is planned to compare NX-5948 against Pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• NX-5948
• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Nurix Therapeutics, Inc. | Conditions: B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Status: NOT_YET_RECRUITING